Illuminating immunotherapy response via precision T cell-targeted PET imaging

被引:0
|
作者
Glazer, Sarah E. [1 ]
Kummar, Shivaani [2 ]
Mittra, Erik [3 ]
机构
[1] Oregon Hlth & Sci Univ, Div Internal Med, Portland, OR USA
[2] Oregon Hlth & Sci Univ, Knight Canc Inst, Div Hematol & Med Oncol, Portland, OR USA
[3] Oregon Hlth & Sci Univ, Div Mol Imaging & Therapy, Portland, OR 97239 USA
关键词
PET; immunotherapy; radiopharmaceuticals; tumor immune microenvironment; predictive biomarkers; PREDICTIVE BIOMARKER; IN-VIVO; EXPRESSION; BLOCKADE; CANCER; INFILTRATION; ACTIVATION; ANTIBODY;
D O I
10.3389/fmed.2024.1233913
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Traditionally, immunotherapy agent selection and treatment strategies are guided by biopsy-based histological information. However, biopsies are limited in that they are invasive, provide static information regarding the tumor immune microenvironment, and only sample a small part of one tumor site. The tumor microenvironment is dynamic and heterogenous. As a result, the immune milieu at one site may be distinct from other metastatic sites. These factors make identifying which patients are likely to respond to different immunotherapies and which harbor intrinsic resistance mechanisms difficult to identify based on a biopsy alone. As such, there is significant interest in alternative methodologies that better characterize the tumor immune microenvironment and monitor immunotherapy response. PET imaging potentially offers a non-invasive way to characterize the tumor immune microenvironment at the primary tumor and metastases and allow for longitudinal characterization. Herein, we review pre-clinically and clinically tested T cell-targeted PET radiopharmaceuticals, as T cells have been the dominant immunotherapy target, and their utility in both evaluating response to immunotherapy and in understanding the systemic immune response to treatment with immunotherapeutics.
引用
收藏
页数:15
相关论文
共 50 条
  • [21] Regeneration of invariant natural killer T (iNKT) cells: application of iPSC technology for iNKT cell-targeted tumor immunotherapy
    Takahiro Aoki
    Shinichiro Motohashi
    Haruhiko Koseki
    Inflammation and Regeneration, 43
  • [22] Natural Killer T Cell-Targeted Immunotherapy Mediating Long-term Memory Responses and Strong Antitumor Activity
    Dashtsoodol, Nyambayar
    Shigeura, Tomokuni
    Tashiro, Takuya
    Aihara, Minako
    Chikanishi, Toshihiro
    Okada, Hiromi
    Hanada, Keigo
    Sano, Hirokazu
    Kurogi, Akihiko
    Taniguchi, Masaru
    FRONTIERS IN IMMUNOLOGY, 2017, 8
  • [23] Cell-targeted steroid signaling in the thymus determines T cell repertoire strength
    Taves, Matthew Donald
    Mittelstadt, Paul
    Presman, Diego
    Hager, Gordon
    Ashwell, Jonathan D.
    JOURNAL OF IMMUNOLOGY, 2019, 202 (01):
  • [24] Cancer stem cell-targeted bio-imaging and chemotherapeutic perspective
    Han, Jiyou
    Won, Miae
    Kim, Ji Hyeon
    Jung, Eugeine
    Min, Kyungim
    Jangili, Paramesh
    Kim, Jong Seung
    CHEMICAL SOCIETY REVIEWS, 2020, 49 (22) : 7856 - 7878
  • [25] A THERANOSTIC DRUG FOR PROSTATE CANCER CAR T CELL IMMUNOTHERAPY AND PET IMAGING
    Arndt, C.
    Koristka, S.
    Berndt, N.
    Bergmann, R.
    Loureiro, L.
    Kotzerke, J.
    Bachmann, M.
    Feldmann, A.
    HUMAN GENE THERAPY, 2019, 30 (12) : A16 - A17
  • [26] B Cell-targeted Immunotherapy for Type 1 Diabetes: What Can Make It Work?
    Hamad, Abdel Rahim A.
    Ahmed, Rizwan
    Donner, Thomas
    Fousteri, Georgia
    DISCOVERY MEDICINE, 2016, 21 (115) : 213 - 219
  • [27] Myeloid Cell-Targeted Nanocarriers Efficiently Inhibit Cellular Inhibitor of Apoptosis for Cancer Immunotherapy
    Koch, Peter D.
    Rodell, Christopher B.
    Kohler, Rainer H.
    Pittet, Mikael J.
    Weissleder, Ralph
    CELL CHEMICAL BIOLOGY, 2020, 27 (01): : 94 - +
  • [28] PET imaging of endogenous markers of T-cell response
    Harsini, Sara
    Alavi, Abass
    Werner, Thomas
    Revheim, Mona-Elisabeth
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [29] Discovery of NKT cells and development of NKT cell-targeted anti-tumor immunotherapy
    Taniguchi, Masaru
    Harada, Michishige
    Dashtsoodol, Nyambayar
    Kojo, Satoshi
    PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES, 2015, 91 (07): : 292 - 304
  • [30] What is the place of recently approved T cell-targeted and B cell-targeted therapies in the treatment of rheumatoid arthritis? Lessons from global clinical trials
    Smolen, Josef S.
    JOURNAL OF RHEUMATOLOGY, 2007, 34 : 15 - 20